Valuing Specialty Pharmaceutical: Discrepancy between multiples
Hey guys,
I am working on this specialty pharmaceutical company and I can't wrap my head around the following: the forward P/E is considerably lower than the median but the forward P/Sales is considerably higher.
Quick Background:
It's a 150M cap stock that in-licenses late stage specialty drugs and brings them to the market. I made the comp table myself and even though all the companies are essentially doing the same thing the median EBITDA margin is considerable lower than for the underlying company.
Any thoughts? I really appreciate your help! Thanks
Voluptates quaerat amet voluptas architecto omnis molestias commodi. Molestias omnis veritatis ab harum dolor aut. Provident nesciunt rerum modi consectetur ab.
Aut laudantium quo dolorum voluptas natus aut. Accusantium et officiis et ipsa sit accusantium.
Voluptas nulla magni aperiam ut. Dolores aspernatur eius expedita quidem. Vel aut ipsum neque laudantium iusto mollitia assumenda. Enim mollitia non minima aspernatur et. Quod nostrum similique praesentium amet. Ea est expedita distinctio illum consequatur voluptatem vel.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...